TECH

Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&D Systems™ AI-Engineered Designer Protein portfolio AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing MINNEAPOLIS, July 8, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems™ AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows. The R&D Systems AI-Engineered Designer Protein platform enables the design and creation of new protein-based solutions to help researchers overcome current variability and scalability challenges in advanced cell culture by improving the stability and activity of critical reagents.

BALA CYNWYD, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.

BALA CYNWYD, Pa., June 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

NEW YORK, June 26, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Bio-Techne Corporation (NASDAQ: TECH ) related to its sale to Merck KGaA.

Bio-Techne Corporation (TECH) M&A Call Transcript

MILWAUKEE, June 25, 2026 /PRNewswire/ -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (NASDAQ: TECH) to Merck KGaA for $73.00 per share in cash. Halper Sadeh encourages Bio-Techne shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Bio-Techne and its board of directors violat.

Bio-Techne stock jumps, with Germany's Merck KGaA buying the company at a 24% premium.

Purchase price of US$73 per share in cash represents an enterprise value of US$11.3 billion (EUR 9.9 billion) Proposed acquisition expected to be immediately accretive to sales growth and EBITDA pre margin post-closing, and EPS pre accretive by year 3 after closing U.S.-based Bio-Techne to bring portfolio with industry-leading multi-omics offering, analytical technologies and integrated workflow solutions across the scientific journey Would deliver on growth agenda of Merck KGaA, Darmstadt, Germany, by expanding presence in high-growth, next-generation life sciences markets and further strengthening the position as a leader along the full life science value chain Would add complementary strengths across research, bioprocessing and advanced therapeutics, bolstering the offering of Merck KGaA, Darmstadt, Germany, in next-generation biology Synergistic platform would broaden offerings, accelerate innovation pipeline of Merck KGaA, Darmstadt, Germany, and increase Bio-Techne's geographic and omnichannel access for customers Merck KGaA, Darmstadt, Germany, expects annual cost synergies of approximately EUR 140 million, which are anticipated to be fully realized by year 3 after closing DARMSTADT, Germany and MINNEAPOLIS, June 25, 2026 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation (NASDAQ: TECH), a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, today entered into a definitive agreement pursuant to which Merck KGaA, Darmstadt, Germany, will, subject to customary closing conditions, acquire Bio-Techne for US$73 per share in cash, representing a total enterprise value of approximately US$11.3 billion (EUR 9.9 billion), a 36% premium to Bio-Techne's one-month volume weighted average trading price. The transaction would bring together two highly complementary and leading life sciences organizations, uniquely positioned to support customers across the full spectrum of life science workflows – from discovery and translational research through development, testing and commercial manufacturing.